Search Results

You are looking at 21 - 30 of 523 items for :

  • Refine by Access: All content x
Clear All
Free access

Ivan Bièche, Carine Chavey, Catherine Andrieu, Muriel Busson, Sophie Vacher, Ludovic Le Corre, Jean-Marc Guinebretière, Sandrine Burlinchon, Rosette Lidereau, and Gwendal Lazennec

III biopsies. CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL8 were then investigated in an independent panel of ERα-positive tumors from 48 postmenopausal breast cancer patients treated with adjuvant tamoxifen alone, of whom 24 relapsed. Overexpression of

Free access

Jolanta Krajewska, Ewa Chmielik, and Barbara Jarząb

). The question how to properly assess the risk of relapse in differentiated thyroid carcinoma (DTC) has been discussed during recent years and finally resulted in a substantial change in our approach to DTC risk stratification, fulfilling evidence

Free access

Riccardo Ponzone, Paola Mininanni, Elisa Cassina, Francesca Pastorino, and Piero Sismondi

oestrogen suppression and also a marginal increase in plasma oestrogens at the time of relapse (see Lønning 2003 for a review). Conversely, extensive data are available on the clinical efficacy of first-generation and second-generation compounds when

Free access

Fulvia Daffara, Silvia De Francia, Giuseppe Reimondo, Barbara Zaggia, Emiliano Aroasio, Francesco Porpiglia, Marco Volante, Angela Termine, Francesco Di Carlo, Luigi Dogliotti, Alberto Angeli, Alfredo Berruti, and Massimo Terzolo

report herein the results of the visits at baseline, +3,+6,+9,+12 months, and the last available follow-up for non-recurring patients. For patients who experienced ACC recurrence, the follow-up immediately preceding the detection of relapse was reported

Free access

Tania Moujaber, Rosemary L Balleine, Bo Gao, Ida Madsen, Paul R Harnett, and Anna DeFazio

LGSC have shown that optimal debulking surgery is associated with improved outcomes ( Nickles Fader et al. 2013 , Grabowski et al. 2016 ). In the relapse setting, two retrospective reviews suggested improved clinical outcome in women with LGSC

Restricted access

Julien Hadoux, Thomas Walter, Christina Kanaan, Ségolène Hescot, Vincent Hautefeuille, Marine Perrier, Igor Tauveron, Sandrine Laboureau, Christine Do Cao, Caroline Petorin, Odile Blanchet, Matthieu Faron, Emmanuelle Leteurtre, Marie-Christine Rousselet, Juliette Joubert Zakeyh, Aude Marchal, Denis Chatelain, Clément Beaulaton, Valérie Hervieu, Catherine Lombard-Bohas, Michel Ducreux, Jean-Yves Scoazec, Eric Baudin, , and

an etoposide/platinum-based regimen (EBR) is also considered an option in some guidelines but with little supportive data to date ( de Mestier et al. 2020 ). In small-cell lung cancer (SCLC) and also in ovarian cancer, a sensitive-relapsed cancer is

Free access

Honglin Chen, Stephen J Libertini, Michael George, Satya Dandekar, Clifford G Tepper, Bushra Al-Bataina, Hsing-Jien Kung, Paramita M Ghosh, and Maria Mudryj

. 2003 ), were isolated in separate laboratories from CWR22-relapsed tumors. Several lines of evidence indicate that they were derived from a common ancestor. Karyotypes of the two cell lines are very similar; both lines shared the same structural

Free access

Danielle Meijer, Anieta M Sieuwerts, Maxime P Look, Ton van Agthoven, John A Foekens, and Lambert C J Dorssers

analysis. Further inclusion criteria were: >100 mg frozen tissue available, invasive breast cancer, no previous other cancer (except basal cell skin cancer or early stage cervical cancer stage Ia/Ib), no second primary breast tumor at first relapse, no

Free access

Atsushi Mizokami, Eitetsu Koh, Kouji Izumi, Kazutaka Narimoto, Masashi Takeda, Seijiro Honma, Jinlu Dai, Evan T Keller, and Mikio Namiki

and their study may be due to a difference in sensitivity for androgens between LNCaP and LAPC4. Several mechanisms explaining why advanced PCa relapses during ADT have been considered ( Feldman & Feldman 2001 , Schroder 2008 ). AR amplification

Free access

Belinda van Zyl, Denise Tang, and Nikola A Bowden

( Stuart et al. 2011 ), a tubulin target that blocks mitotic spindle assembly and halts cell division ( Kampan et al. 2015 ). Many other agents are used in combination with platinum chemotherapies after relapse. These incude pegylated doxorubicin (TopII